Although our findings validate Ang2 as a valuable biomarker of liver fibrosis, they are preliminary; thus, further studies in extended cohorts of patients should be performed to verify the significance of our model in monitoring the evolution of CHC and its potential to predict the progression of other CLDs. The gene discussed is ANGPT2; the disease is cryohydrocytosis.